Xinde Technology valued at 1.8 billion, rushing to the Hong Kong Stock Exchange, Sumitomo Corporation and Sany Heavy Industry among the shareholders

Ruicai Finance Wu Wenting Recently, Shandong Xinde Technology Co., Ltd. (hereinafter referred to as “Xinde Technology”) submitted its prospectus to the Hong Kong Stock Exchange, with ICBC International and Zhongtai International serving as joint sponsors.

Founded in 1999, Xinde Technology is an animal health company.

The company mainly engages in the research, development, production, and sales of a full range of animal health and supporting products. Its products include veterinary biological products (such as vaccines, antibodies, transfer factors, etc.), traditional Chinese veterinary medicine, chemical drug formulations, animal feed, and feed additives, aiming to prevent, diagnose, treat, and control diseases in poultry, livestock, aquatic animals, and pets.

According to data from Zhuo Shi Consulting, based on 2024 revenue, the company ranks ninth among domestic manufacturers in China’s animal health market and is among the top three in China’s poultry veterinary biological products market.

According to the prospectus, in 2023-2024, Xinde Technology achieved revenues of 985 million yuan and 982 million yuan, respectively; profits for the year were 34.763 million yuan and 28.118 million yuan.

In the first three quarters of 2025, the company achieved revenue of 877 million yuan, a year-on-year increase of 25.15%; profits during this period were 55.671 million yuan, a year-on-year increase of 117.55%.

It is worth noting that Xinde Technology has completed three rounds of financing, and after the latest round, its valuation is approximately 1.8 billion yuan.

Before the IPO, Sumitomo Corporation held a 22.57% stake, and Sany Hong Kong, a subsidiary of the heavy machinery giant Sany Heavy Industry, held a 2.98% stake.

Related companies: Sany Heavy Industry (sh600031), Xinde Technology